digital health companies glp-1 programs The future of drugs in healthcare: Vital's role in enhancing metabolic treatment Dr. Craig Primack talks Hims

We want to identify really useful peptides that can be leveraged and advanced as treatment for human diseases for which there is no solution at the moment. One potential prospect is MOTs-C, which Cohen discovered and has studied in Phase 1A and Phase 1B trials

1.072-1.082 g/ml

Once at the inner mitochondrial membrane, SS-31: Stabilizes cardiolipin: prevents the oxidative modification that disrupts membrane structure and ETC function Preserves cytochrome c interaction: cytochrome c is a protein that must remain loosely associated with cardiolipin for proper ETC function

Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies

4% report awareness of increased heart rate